Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | R. S. Meehan, A. P. Chen, G. Helen O'Sullivan C., J. M. Collins, S.Kummar, L. Anderson, K. Ishii, J. Zlott, L. Rubinstein, Y. Horneffer, L. Juwara, W. Jeong, N. Takebe, R. J. Kinders, R. E. Parchment, J. H. Doroshow | ||||||||||||
Title | A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas. | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/168775-176 | ||||||||||||
Abstract Text | J Clin Oncol 34, 2016 (suppl; abstr 2556) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TRC102 | Methoxyamine|TRC-102 | TRC102 (Methoxyamine) inhibits the base excision repair pathway, potentially resulting in increased sensitivity to chemotherapeutic agents and anti-tumor activity (J Clin Oncol 34, 2016 (suppl; abstr 2556), PMID: 23054206, PMID: 32556884). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|